Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug CRB-701 targets Nectin-4 in advanced tumors

NCT ID NCT06265727

Disease control Sponsor: Corbus Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called CRB-701, which is designed to find and attack cancer cells that have a protein called Nectin-4 on their surface. The trial includes 348 adults with advanced solid tumors that have not responded to standard treatments. Researchers aim to find a safe and effective dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CRB-701 (an antibody-drug conjugate that targets Nectin-4, a protein on cancer cells) and an anti-PD-1 checkpoint inhibitor
What this could lead to
If successful, this could provide a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or may have significant side effects. Results may not apply to all cancer types.
Why investors are watching

Corbus Pharmaceuticals is testing CRB-701, an antibody-drug conjugate that targets a protein called nectin-4, in patients with advanced solid tumors. For a very small company, this early-stage trial is a central test of whether its lead drug candidate can safely shrink tumors and in which cancers. The result will shape the company's future research priorities and its ability to attract partners or funding.

If it works: If the trial shows CRB-701 is safe and shrinks tumors in some patients, Corbus could advance the drug to later-stage testing and potentially broaden its pipeline. A positive readout may also increase interest from larger drug companies looking to collaborate or license the drug.

If it fails: The trial could fail to show enough safety or tumor response, which would likely force Corbus to abandon or rethink CRB-701. Early-phase cancer trials often fail, and for a micro-cap company, a setback with its main drug candidate could be a serious blow to its prospects.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 348 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed having exhausted all appropriate lines of therapy or have no other standard therapy with proven clinical benefit. In Part C, HNSCC participants may enroll as first-line therapy. Exclusion Criteria: * Active of uncontrolled CNS metastases * History of solid tumors other than the diseases under study * History of and/or current cardiovascular events or conditions in the previous 6 months * Pre-existing \>/= Grade 2 neuropathy * Hemoglobin A1C (HbA1C) \>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy * Active ocular disease at baseline * Chronic severe liver disease or live cirrhosis * Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study * Other significant cormorbidities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    35 sites in 6 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Aresnsia Research Clinic Bucharest

    RECRUITING

    Bucharest, 22328, Romania

    Contact Email: •••••@•••••

  • Aresnsia Research Clinic Cluj-Napoca

    RECRUITING

    Cluj-Napoca, 400015, Romania

    Contact Email: •••••@•••••

  • Barcelona IOB Hospital Quironsalud (NEXT)

    RECRUITING

    Barcelona, 08023, Spain

    Contact Email: •••••@•••••

  • CHU de Poitiers

    RECRUITING

    Poitiers, 86000, France

    Contact Email: •••••@•••••

  • Careggi University Hospital

    RECRUITING

    Florence, 50314, Italy

    Contact Email: •••••@•••••

  • Carolina BioOncology Institute

    ACTIVE_NOT_RECRUITING

    Huntersville, North Carolina, 28078, United States

  • Centro Richerche Cliniche di Verona

    RECRUITING

    Verona, 37134, Italy

    Contact Email: •••••@•••••

  • Centrul de Oncologie Euroclinic

    RECRUITING

    Iași, 700106, Romania

    Contact Email: •••••@•••••

  • Centrul de Oncologie Sf. Nectarie

    RECRUITING

    Iași, 200347, Romania

    Contact Email: •••••@•••••

  • City of Hope Cancer Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Email: •••••@•••••

  • Dana-Faber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • European Institute of Oncology IRCCS

    RECRUITING

    Milan, 20141, Italy

    Contact Email: •••••@•••••

  • Florida Cancer Specialists

    RECRUITING

    Orlando, Florida, 32806, United States

    Contact Email: •••••@•••••

  • Fondazione Policlinico Gemelli, IRCCS

    RECRUITING

    Rome, 00168, Italy

    Contact Email: •••••@•••••

  • Fred Hutchinson Cancer Center at University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

  • Fundacion Jimenez Diaz (START)

    RECRUITING

    Madrid, 28040, Spain

    Contact Email: •••••@•••••

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

    Contact Email: •••••@•••••

  • Guy's and St Thomas' Clinical Research Facility

    RECRUITING

    London, SE1 9RT, United Kingdom

    Contact Email: •••••@•••••

  • Helen Diller Family Comprehensive Cancer Center - UCSF

    RECRUITING

    San Francisco, California, 94115, United States

    Contact Email: •••••@•••••

  • Hope and Healing Cancer Center

    ACTIVE_NOT_RECRUITING

    Hinsdale, Illinois, 60521, United States

  • Hospital Clinico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

    Contact Email: •••••@•••••

  • ICM-Val d'Aurelle

    RECRUITING

    Montpellier, 34298, France

    Contact Email: •••••@•••••

  • Imperial Experimental Cancer Medicine Centre

    RECRUITING

    London, W12 0NN, United Kingdom

    Contact Email: •••••@•••••

  • Institut de Cancerologie de l'Ouest

    RECRUITING

    Saint-Herblain, 44085, France

    Contact Email: •••••@•••••

  • Institute of Oncology/ARENSIA Exploratory Medicine

    WITHDRAWN

    Chisinau, MD-2025, Moldova

  • Leeds University Hospitals NHS Trust

    RECRUITING

    Leeds, LS9 7LP, United Kingdom

    Contact Email: •••••@•••••

  • Moores Cancer Centre at UC San Diego Health

    RECRUITING

    San Diego, California, 92037, United States

    Contact Email: •••••@•••••

  • Nebraska Hematology Oncology

    ACTIVE_NOT_RECRUITING

    Lincoln, Nebraska, 68506, United States

  • O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact Email: •••••@•••••

  • Rocky Mountain Cancer Centres

    ACTIVE_NOT_RECRUITING

    Denver, Colorado, 80218, United States

  • Texas Oncology

    RECRUITING

    Tyler, Texas, 75702, United States

    Contact Email: •••••@•••••

  • The Christie Hospital

    RECRUITING

    Manchester, M20 4BX, United Kingdom

    Contact Email: •••••@•••••

  • University of Birmingham NHS Foundation Trust

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

    Contact Email: •••••@•••••

  • University of Cambridge NHS Foundation Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

    Contact Email: •••••@•••••

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

  • University of Liverpool - Clatterbridge Medical Centre

    RECRUITING

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

    Contact Email: •••••@•••••

  • University of Southampton

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

    Contact Email: •••••@•••••

  • Vall d-Hebron Institut d'Oncologia

    RECRUITING

    Barcelona, 08035, Spain

    Contact Email: •••••@•••••

  • Velindre Cancer Centre

    RECRUITING

    Cardiff, CF15 7QZ, United Kingdom

    Contact Email: •••••@•••••

  • Virginia Cancer Specialists

    ACTIVE_NOT_RECRUITING

    Fairfax, Virginia, 22031, United States

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.